Tower Research Capital (TRC)’s Galectin Therapeutics Inc. - Warrants GALTW Stock Holding History

Tower Research Capital (TRC)’s Portfolio GALTW Stock Details GALTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-133	Closed	–	–	4601
2016 Q4	$0	Hold	133	–	–	﹤0.01%	4972
2016 Q3	$0	Buy	+133	New	+$47	﹤0.01%	5240

Tower Research Capital (TRC)'s GALTW Position: Q1 2017 in Review

Tower Research Capital (TRC) sold out of Galectin Therapeutics Inc. - Warrants (GALTW) in Q1 2017, closing a stake of 133 shares.

Tower Research Capital (TRC) first reported a position in GALTW in Q3 2016 and held it in 2 quarters. The position peaked at $0 in Q4 2016. 0 funds tracked by Wall St. Rank hold GALTW as of Q1 2017.

Tower Research Capital (TRC) reported no remaining Galectin Therapeutics Inc. - Warrants position as of Q1 2017 after selling out during the quarter.
Tower Research Capital (TRC) sold 133 Galectin Therapeutics Inc. - Warrants shares in Q1 2017.
Tower Research Capital (TRC) first reported a position in Galectin Therapeutics Inc. - Warrants in Q3 2016 and held it in 2 quarters.
Tower Research Capital (TRC)'s Galectin Therapeutics Inc. - Warrants position peaked at $0 in Q4 2016.
0 funds tracked by Wall St. Rank held Galectin Therapeutics Inc. - Warrants as of Q1 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.